Valneva SE (VALN) Accounts Payables (2020 - 2026)
Valneva SE (VALN) posted Accounts Payables of $25.5 million for Q1 2026, down 10.63% sequentially from $28.6 million in Q4 2025, and down 12.81% YoY from $29.3 million in Q1 2025.
Valneva SE (VALN) Accounts Payables (2020 - 2026) Analysis & Trends
Valneva SE has reported Accounts Payables for 7 years, with the latest figure at $25.5 million in Q1 2026.
- Quarterly Accounts Payables fell 12.81% year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.5 million (down 12.81% YoY) and the FY2025 annual result came in at $28.6 million, down 25.7% from the prior year.
- Accounts Payables eased to $25.5 million in Q1 2026 per VALN's latest filing, from $28.6 million in the prior quarter.
- Over five years, Accounts Payables peaked at $102.6 million in Q3 2023 and troughed at $23.9 million in Q2 2025.
- A 5-year average of $49.5 million and a median of $38.0 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 35.71% in 2023, then plunged 54.08% in 2024.
- Over 5 years, Accounts Payables stood at $42.3 million in 2022, then gained by 12.61% to $47.7 million in 2023, then fell by 20.37% to $38.0 million in 2024, then slipped by 24.75% to $28.6 million in 2025, then fell by 10.63% to $25.5 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $25.5 million, $28.6 million, and $35.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 26.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.63 Mn |
| Mar 31, 2026 | 25.53 Mn |
| Dec 31, 2025 | 28.57 Mn |
| Sep 30, 2025 | 35.21 Mn |
| Jun 30, 2025 | 23.90 Mn |
| Mar 31, 2025 | 29.28 Mn |
| Dec 31, 2024 | 37.96 Mn |
| Sep 30, 2024 | 47.11 Mn |
| Jun 30, 2024 | 35.16 Mn |
| Mar 31, 2024 | 36.40 Mn |
| Dec 31, 2023 | 47.67 Mn |
| Sep 30, 2023 | 102.59 Mn |
| Jun 30, 2023 | 75.30 Mn |
| Mar 31, 2023 | 35.98 Mn |
| Dec 31, 2022 | 42.33 Mn |
| Sep 30, 2022 | 75.59 Mn |
| Jun 30, 2022 | 89.32 Mn |
| Mar 31, 2022 | 74.38 Mn |
| Dec 31, 2021 | 77.93 Mn |
| Dec 31, 2020 | 43.18 Mn |